AroCell AB: AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK Nat...
September 26 2017 - 5:00AM
AroCell AB (publ) announces today
that a research poster submitted by Jagarlamudi K.K. et al. entitled" AroCell TK 210 ELISA may complement
pro PSA and the prostate health index in differentiating
non-cancerous from cancerous conditions in prostate disease" has
been accepted by the UK NICR for presentation at its annual meeting
in November 5-8, 2017.
Thymidine kinase 1 (TK1) is a well-known cell
proliferation biomarker. The purpose of this study was to compare
the TK1 assayed with the AroCell TK 210 ELISA kit with PSA, free
PSA, pro PSA and PHI (Prostate Health Index) in men with
non-cancerous prostate conditions and patients with confirmed
prostate cancer.
Serum samples with known PSA values from subjects
investigated for prostate cancer were collected by the University
Medical Centre, Ljubljana. Overall, AroCell TK 210 ELISA results
showed significant correlation with PHI (r = 032, P = 0.0017) and
pro PSA
(r = 021 P = 0.044) but not with free PSA or PSA. Combining the TK
210 value with the PHI or pro PSA value increased the diagnostic
accuracy for prostate cancer compared with either individually.
CEO Jan Stålemark states "We are delighted that
this preliminary study demonstrated that serum TK1 assayed with
AroCell TK 210 ELISA kit can differentiate between non-cancerous
conditions and prostate cancer patients with a similar accuracy to
that of pro PSA or PHI. Further clinical studies will
establish the capacity of AroCell TK 210 ELISA to complement pro
PSA and PHI in distinguishing between non-cancerous and prostate
cancer, potentially providing another tool in prostate cancer
management".
This data was previously presented at the American
Academy for Cancer Research Annual Meeting April 2017.
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 11.00 CET on 26 September 2017.
About AroCell
AroCell AB (publ) is a Swedish
company that develops standardized modern blood tests to support
the prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure (Thymidine
Kinase 1 (TK1) protein levels, which provide valuable information
about the speed of cell turnover. A tumor has high cell turnover
(speed of cell division and cell death) and as a result TK1 can be
detected in the blood with a simple laboratory test, called TK 210
ELISA. The test provides valuable clinical information for
prognosis and optimization of treatment strategy. The test may also
be used for monitoring disease relapse. AroCell (AROC) is listed at
Nasdaq First North and has about 2,600 shareholders. For more
information, please see www.arocell.com.
Redeye AB is AroCell's Certified Adviser.
AroCell press release 26 Sept
2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Oct 2023 to Oct 2024